TAUNS Laboratories, Inc. Logo

TAUNS Laboratories, Inc.

Develops and sells in vitro diagnostics and research reagents, like antigen tests, globally.

197A | T

Overview

Corporate Details

ISIN(s):
JP3452250008
LEI:
Country:
Japan
Address:
伊豆の国市神島761番1
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TAUNS Laboratories, Inc., founded in 1987, is a company engaged in the development, manufacture, and sale of in vitro diagnostics (IVD) and research reagents. The company's mission is to enrich lives and provide peace of mind through its proprietary diagnostic technologies. Its main products include antigen test kits for infectious diseases and various analytical reagents. A key focus for the company is the development of patient-friendly products for global consumption, facilitated through its export and import operations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-25 09:49
Regulatory News Service
確認書
Japanese 8.1 KB
2025-09-25 09:47
Annual Report
有価証券報告書-第10期(2024/07/01-2025/06/30)
Japanese 2.0 MB
2025-02-13 07:30
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-02-13 07:30
Interim Report
半期報告書-第10期(2024/07/01-2025/06/30)
Japanese 174.5 KB
2024-09-30 03:19
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2024-09-27 08:00
Registration Form
確認書
Japanese 8.1 KB
2024-09-27 08:00
Governance Information
内部統制報告書-第9期(2023/07/01-2024/06/30)
Japanese 22.1 KB
2024-09-27 08:00
Annual Report
有価証券報告書-第9期(2023/07/01-2024/06/30)
Japanese 1.9 MB
2024-06-12 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB
2024-06-04 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB
2024-05-17 08:00
Registration Form
有価証券届出書(新規公開時)
Japanese 4.7 MB

Automate Your Workflow. Get a real-time feed of all TAUNS Laboratories, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAUNS Laboratories, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAUNS Laboratories, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America ABUS

Talk to a Data Expert

Have a question? We'll get back to you promptly.